Analgesic Efficacy and Safety of ADL5859 in Subjects With Acute Dental Pain After Third Molar Extraction

Completed · Phase 2 · Has a placebo group

Conditions studied: Acute Pain

In brief

The objective of this study is to evaluate the analgesic efficacy and safety of ADL5859 compared with placebo and an active control (ibuprofen) in subjects with acute dental pain after third molar extraction.

Key facts

Study ID

NCT00993863

Run by

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

People needed

201

Starts

2007-06-01

Last updated by the study team

2015-07-17

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: not accepted.

Where it is running

• SCIREX Research Center — Austin, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.